Literature DB >> 21998047

Imaging study of early hepatocellular carcinoma: usefulness of gadoxetic acid-enhanced MR imaging.

Katsuhiro Sano1, Tomoaki Ichikawa, Utaroh Motosugi, Hironobu Sou, Ali M Muhi, Masanori Matsuda, Masayuki Nakano, Michiie Sakamoto, Tadao Nakazawa, Masami Asakawa, Hideki Fujii, Takatoshi Kitamura, Nobuyuki Enomoto, Tsutomu Araki.   

Abstract

PURPOSE: To describe imaging findings of early hepatocellular carcinoma (HCC) at gadoxetic acid-enhanced magnetic resonance (MR) imaging, dynamic contrast material-enhanced computed tomography (CT), CT during arterial portography (CTAP), and CT during hepatic arteriography (CTHA) and to compare the diagnostic performance of each modality for small (≤ 2 cm) HCC.
MATERIALS AND METHODS: The institute ethics committee deemed study approval unnecessary. One hundred eight resected small lesions in 64 patients were diagnosed as a dysplastic nodule (DN) (n = 12), progressed HCC (n = 66), or early HCC (n = 30). All but two patients underwent all imaging examinations. The imaging characteristics of the lesions with each modality were determined. To evaluate the diagnostic performance of the modalities, two radiologists graded the presence of HCC with use of a five-point confidence scale. The area under the receiver operating characteristic curve (A(z)), sensitivity, and specificity of each modality were compared.
RESULTS: The imaging features that are statistically significant for differentiating an early HCC from a DN include fat-containing lesions at dual-echo T1-weighted MR imaging (seen in 16 of the 30 early HCCs and none of the DNs), low attenuation at unenhanced CT (seen in 13 of the 30 early HCCs and none of the DNs), low attenuation at CTAP (seen in 11 of the 30 early HCCs and none of the DNs), and low signal intensity at hepatocyte phase gadoxetic acid-enhanced MR imaging (seen in 29 of the 30 early HCCs and none of the DNs). The diagnostic performance of gadoxetic acid-enhanced MR imaging (A(z), 0.98 and 0.99) was significantly greater than that of contrast-enhanced CT (A(z), 0.87) and CTHA-CTAP (A(z), 0.85 and 0.86) owing to its significantly higher sensitivity (P < .001).
CONCLUSION: Gadoxetic acid-enhanced MR imaging is the most useful imaging technique for evaluating small HCC, including early HCC. © RSNA, 2011.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21998047     DOI: 10.1148/radiol.11101840

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  98 in total

1.  The essence of the Japan Radiological Society/Japanese College of Radiology Imaging Guideline.

Authors:  Yasuyuki Yamashita; Sadayuki Murayama; Masahiro Okada; Yoshiyuki Watanabe; Masako Kataoka; Yasushi Kaji; Keiko Imamura; Yasuo Takehara; Hiromitsu Hayashi; Kazuko Ohno; Kazuo Awai; Toshinori Hirai; Kazuyuki Kojima; Shuji Sakai; Naofumi Matsunaga; Takamichi Murakami; Kengo Yoshimitsu; Toshifumi Gabata; Kenji Matsuzaki; Eriko Tohno; Yasuhiro Kawahara; Takeo Nakayama; Shuichi Monzawa; Satoru Takahashi
Journal:  Jpn J Radiol       Date:  2016-01       Impact factor: 2.374

2.  Early hepatocellular carcinoma: definition and diagnosis.

Authors:  M Kudo
Journal:  Liver Cancer       Date:  2013-04       Impact factor: 11.740

Review 3.  Appearance of hepatocellular carcinoma on gadoxetic acid-enhanced hepato-biliary phase MR imaging: a systematic review.

Authors:  Paola Erra; Marta Puglia; Alfonso Ragozzino; Simone Maurea; Raffaele Liuzzi; Giuseppe Sabino; Luigi Barbuto; Alberto Cuocolo; Massimo Imbriaco
Journal:  Radiol Med       Date:  2015-04-22       Impact factor: 3.469

4.  Role of MRI with hepatospecific contrast agent in the identification and characterization of focal liver lesions: pathological correlation in explanted livers.

Authors:  Antonio Orlacchio; Fabrizio Chegai; Sebastiano Fabiano; Stefano Merolla; Valentina Funel; Francesca Di Giuliano; Matteo Manuelli; Giuseppe Tisone; Simona Francioso; Mario Angelico; Giampiero Palmieri; Giovanni Simonetti
Journal:  Radiol Med       Date:  2016-04-21       Impact factor: 3.469

Review 5.  Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.

Authors:  Masao Omata; Ann-Lii Cheng; Norihiro Kokudo; Masatoshi Kudo; Jeong Min Lee; Jidong Jia; Ryosuke Tateishi; Kwang-Hyub Han; Yoghesh K Chawla; Shuichiro Shiina; Wasim Jafri; Diana Alcantara Payawal; Takamasa Ohki; Sadahisa Ogasawara; Pei-Jer Chen; Cosmas Rinaldi A Lesmana; Laurentius A Lesmana; Rino A Gani; Shuntaro Obi; A Kadir Dokmeci; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2017-06-15       Impact factor: 6.047

Review 6.  Advances in computed tomography and magnetic resonance imaging of hepatocellular carcinoma.

Authors:  Tiffany Hennedige; Sudhakar K Venkatesh
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

7.  Liver stiffness measured by magnetic resonance elastography as a risk factor for hepatocellular carcinoma: a preliminary case-control study.

Authors:  Utaroh Motosugi; Tomoaki Ichikawa; Tsuyota Koshiishi; Katsuhiro Sano; Hiroyuki Morisaka; Shintaro Ichikawa; Nobuyuki Enomoto; Masanori Matsuda; Hideki Fujii; Tsutomu Araki
Journal:  Eur Radiol       Date:  2012-07-20       Impact factor: 5.315

8.  Non-alcoholic fatty liver disease-associated hepatocellular carcinoma: effect of hepatic steatosis on major hepatocellular carcinoma features at MRI.

Authors:  Scott M Thompson; Ishan Garg; Eric C Ehman; Shannon P Sheedy; Candice A Bookwalter; Rickey E Carter; Lewis R Roberts; Sudhakar K Venkatesh
Journal:  Br J Radiol       Date:  2018-08-29       Impact factor: 3.039

Review 9.  JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan.

Authors:  Masatoshi Kudo; Osamu Matsui; Namiki Izumi; Hiroko Iijima; Masumi Kadoya; Yasuharu Imai; Takuji Okusaka; Shiro Miyayama; Kaoru Tsuchiya; Kazuomi Ueshima; Atsushi Hiraoka; Masafumi Ikeda; Sadahisa Ogasawara; Tatsuya Yamashita; Tetsuya Minami; Koichiro Yamakado
Journal:  Liver Cancer       Date:  2014-10       Impact factor: 11.740

10.  Gadoxetic acid-enhanced MRI for hepatocellular carcinoma and hypointense nodule observed in the hepatobiliary phase.

Authors:  Elsa Iannicelli; Marco Di Pietropaolo; Massimo Marignani; Chiara Briani; Giulia Francesca Federici; Gianfranco Delle Fave; Vincenzo David
Journal:  Radiol Med       Date:  2013-12-03       Impact factor: 3.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.